Company presentations
Allegria Therapeutics is a Basel-based biopharma start-up established in 2023 with a highly differentiated portfolio of therapeutic approaches to target mast cells as drivers of allergy and inflammatory disease.
Our first-in-class approaches modulate mast cell activity directly and selectively to attain a combination of better efficacy and safety as compared to approaches being pursued thus far.
May 6, 13:30 - 13:45, room Singapore
Aptar Pharma, your go-to drug delivery expert, from formulation to patient, supports pharmaceutical companies develop safe, compliant medicines for a wide range of delivery routes. Our digital healthcare solutions and investments in R&D and innovation allow us to offer proven drug delivery solutions to improve patient outcomes. Our global GMP manufacturing sites help accelerate and derisk drug development. Aptar Pharma is part of AptarGroup,Inc.(NYSE: ATR)www.aptar.com/pharma
May 6, 14:00 - 14:15, room Osaka/Samarkand
Arakena Pharmceuticals GmbH is a Basel-based biopharma start-up with a unique portfolio of potent G protein-coupled receptor kinase (GRK) inhibitors with potential for first-in-class treatment in cardiomyopathies, cardiovascular and metabolic diseases. Cardiomyopathies are responsible for heart failure, sudden cardiac death and hospitalisation due to major cardiovascular events. GRK inhibitors have demonstrated promising efficacy in a range of different heart disease models.
May 6, 14:45 - 15:00, room Singapore
Araris Biotech AG is a wholly owned subsidiary of Taiho Pharmaceutical (part of the Otsuka Holdings), pioneering a novel, best-in-class technology platform generating multi-payload antibody-drug conjugates (ADCs) in one step on native antibodies, without requiring any antibody engineering or glycan remodelling. Araris ADCs have showed excellent stability and antibody-like PK properties, leading to higher efficacy and tolerability against multiple commercially available ADCs.
May 6, 12:30 - 12:45, room Singapore
ARTBIO is a clinical-stage company developing a new class of alpha radioligand therapies (ART) using the alpha-emitting Pb212, which delivers powerful, short-lived bursts of energy into tumors for greater efficacy than other isotopes. ARTBIO's proprietary Alpha-DirectTM technology enables Pb212 production in a distributed manufacturing network that delivers its pipeline to patients. AB001 enters the clinic for prostate cancer in 2025; 3 additional programs advance quickly.
May 6, 12:45 - 13:00, room Montreal
Atopia Therapeutics, is developing ATP-R13, a first-in-class disease-modifying oral immunotherapy targeting allergic diseases like asthma, atopic dermatitis, and food allergies. Derived from a natural bacterial protein, ATP-R13 restores immune tolerance by inducing regulatory T cells (Tregs), addressing the root cause of allergic inflammation. Atopia aims to provide curative solutions beyond symptom management and is advancing ATP-R13 toward clinical development
May 6, 13:45 - 14:00, room Singapore
Azafaros is a clinical-stage biotech company developing nizubaglustat, an orally available, brain-penetrant small molecule with a unique dual mode of action, targeting key pathways in GM1/GM2 gangliosidoses, Niemann-Pick type C (NPC), and other severe metabolic disorders. Following a successful Ph 2 study, Azafaros is preparing for global Ph 3 trials in GM1/GM2 gangliosidoses and NPC. In parallel, the company continues to expand its pipeline through cutting-edge research.
May 6, 14:45 - 15:00, room Montreal
Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. We have preclinical and clinical anti-infective assets in our portfolio. We are located in the Basel area and listed on the SIX Swiss Exchange (SIX: BSLN).
May 5, 16:00 - 16:15, room Osaka/Samarkand
Belach Bioteknik has over 40 years of experience designing, manufacturing, and maintaining biotechnological equipment and bioprocess systems. Belach products and systems are typically tailored to individual user requirements, from lab-scale experimental bioreactors to pilot and production bioreactor systems. Belach Bioteknik serves clients in Scandinavia, Europe, and the USA. Besides distributing new equipment, Belach provides reliable yearly maintenance and service.
May 5, 14:30 - 14:45, room Osaka/Samarkand
Cellis AG is developing Macrophage Drug Conjugates (MDC). Our innovative approach is based on the groundbreaking discovery of the TRAIN mechanism unveiled by our team. Our technology works as a natural “Trojan Horse.” Our technology works as a natural “Trojan Horse.” By administering only a fraction of the drug dosage twice, we achieve a robust and durable activation of the immune system that leads to tumor regression and the development of anti-tumor resistance.
May 6, 15:45 - 16:00, room Singapore
Celonic is a “Pure Play” Mammalian Biologics CDMO. It's mission is to help its customers, primarily small to large Biotech companies, bring life-saving drugs to the market using innovative, “next generation” bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial mid-size GMP manufacturing facilities in Heidelberg, Germany.
May 5, 14:30 - 14:45, room Montreal
May 6, 12:30 - 12:45, room Montreal
CinnaGen Co. was founded in 1994 with the goal of manufacturing hi-tech products in biotechnology and related fields. Since its start of operation with 4 scientists, CinnaGen has grown to become the biggest bio-pharmaceutical manufacturer and biotech exporter in the MENA region. Our aim is to use our expertise to identify and acquire selected products through strategic partnerships to promote sustainable development in human health.
May 5, 14:45 - 15:00, room Osaka/Samarkand
Concept Life Sciences is a UK-based drug discovery CRO , helping global pharma and biotech companies accelerate their drug candidate to clinic by offering integrated drug discovery programs as well as high quality solutions in Biology, Chemistry, ADME/ DMPK, Toxicology and GMP manufacturing. Concept Life Sciences has helped pharma and biotech companies accelerate 30 candidates to preclinical stage, 21 candidates to clinic, and 4 candidates to market.
May 6, 16:15 - 16:30, room Osaka/Samarkand
Cube Biotech specializes in solving complex problems in protein research, with a specific emphasis on the challenging class of membrane proteins. We cover all stages of protein preparation utilizing our NativeMP copolymer stabilization platform, protein purification capabilities, biophysical target characterization applications, and structure determination via cryo-EM or crystallography. Cube Biotech also offers active, full-length protein targets with a native structure.
May 5, 17:15 - 17:30, room Osaka/Samarkand
Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™,
May 5, 16:45 - 17:00, room Osaka/Samarkand
FimmCyte is a Swiss biotech developing disease modifying therapies for chronic diseases through elimination of diseased cells directly. FimmCyte has a pipeline of multi-specifics with the two most advanced assets ready for IND and CMC for endometriosis and an organ fibrosis.
May 6, 13:00 - 13:15, room Singapore
Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.
May 5, 14:45 - 15:00, room Montreal
Helbling is an internationally active and independent engineering and consulting firm employing more than 600 professionals with a focus on innovation and product development, management consulting, energy/infrastructure, mergers/acquisitions, restructuring, and real estate. We develop technologically sophisticated products for our clients, from conceptualization to industrialization, and bring innovation to life – a matter of heart, soul and actions.
May 5, 15:45 - 16:00, room Osaka/Samarkand
HemostOD is an early pre-clinical stage Swiss company producing "ex vivo", adult stem cell-derived engineered platelets, for infusion in patients suffering low platelet counts, as in thrombocytopenia and when a patient's own immune system attacks platelet transfusions from human donors.The platelets are manufactured from megakaryocyte cells and mimic the structure and biological properties of fresh human platelets, but with greatly reduced immunogenicity and purer quality.
May 6, 16:00 - 16:15, room Singapore
ImmunOs’ approach is based on the identification of specific human leukocyte antigen (HLA) molecules that hyper-activate the immune system of patients with severe autoimmune disorders. The company has utilized this discovery to develop an HLA-based technology platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.
May 5, 15:15 - 15:30, room Montreal
KBI Biopharma is a global CDMO providing fully integrated, accelerated drug development and biologics manufacturing expertise. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. KBI works closely to personalize and rapidly accelerate drug development programs.
May 6, 14:45 - 15:00, room Osaka/Samarkand
Abstract: Pharmaceutical companies are consistently becoming more and more innovative; this is leading to the increased complexity of the candidate molecules. Understanding the molecular properties at an early stage of development is critical to have a successful and competitive molecule. At KBI, we have established an efficient platform employing cutting edge analytics to compare multiple developmental candidates. The platform evaluates the molecule for several key attributes including thermal stability, aggregation propensity, hydrophobicity, as well as critical effector functions assays. Benchmarking against clinically successful candidates is the hallmark of our developability/manufacturability assessment. Data is presented in a fit for purpose regulatory ready and QbD adaptable result summary. Derisking the molecules through low volume, high-throughput methods have prevented selecting candidates with avoidable CMC risks.
Labcorp is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Learn more about us at www.labcorp.com.
May 5, 15:30 - 15:45, room Osaka/Samarkand
Legacy Healthcare is developing treatments for autoimmune diseases. Its first drug, Cinainu, demonstrated efficacy and safety in a Ph 2/3 trial in children and adolescents with Alopecia Areata. Cinainu is a first-in-class botanical drug with patent protection until 2043. Thanks to unparallel safety and efficacy, physicians say Cinainu would be their first-line treatment in a market expected to generate $5b by 2030. The company is raising funds to pursue FDA track.
May 5, 16:15 - 16:30, room Montreal
Swiss biotech company in immunology and inflammation (I&I). Our lead assets are in the allergy space, the fastest growing Type 2 immunology market with major unmet medical need.
We are currently raising our series B (USD 60M). 1/3 of the 60M series B has been already committed by current investors.
Phase 1 for our lead asset (antibody for peanut allergy) is expected to start in Q4 2025.
• 100% protection
• fewer injections/year (2 injections/year)
• rapid onset of immunity
May 5, 15:45 - 16:00, room Singapore
Menarini Biotech, a boutique, pure-play CDMO where we specialise in antibody discovery, development, and manufacture. We offer competitive pricing, fast clinical batch execution, regulatory expertise to accelerate biologics incl. enzymes, monoclonal antibodies, bi-specifics, fusion proteins, and ADCs from Research to FIH. From DNA to TOX in less then 6 months, GMP in 9 months. Those CMC services include manufacturability and scalability to ensure a seamless transition to GMP.
May 5, 17:00 - 17:15, room Osaka/Samarkand
metaLead is a spin-out from the University of Zurich pioneering innovative therapies for metal-related diseases. Our platform develops first-in-class metal-binding peptides with exceptional affinity and selectivity to desired metals. Our lead program addresses Wilson disease, a rare genetic condition causing the accumulation of toxic amounts of copper in the liver and brain. We combine cutting-edge science, drug development expertise, and patient-driven innovation.
May 6, 13:15 - 13:30, room Singapore
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.
May 6, 14:15 - 14:30, room Osaka/Samarkand
Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators — molecules that increase or decrease the activity of target receptors by binding outside of the “active site” where endogenous ligands and traditional drugs operate. Through this platform, Neurosterix’s novel drug candidates have the potential to provide me
May 6, 15:00 - 15:15, room Singapore
Parexel is among the world’s largest CROs, providing full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, we collaborate with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials for patients.
May 6, 12:45 - 13:00, room Osaka/Samarkand
ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms including NBE, AAV, mRNA and LV development candidates. Our services comprise extended characterization as well as release and stability testing.
May 6, 15:00 - 15:15, room Osaka/Samarkand
PSI CRO is a global Swiss-based full-service contract research organization (CRO), the only Swiss CRO organically grown since 1995 to operate globally across 56 countries with 3,000 full-time staff (as of December 2024).
PSI specializes in the set-up and management of global pivotal registrational clinical trials and is known for its unfailing commitment to timely delivery.
May 5, 15:15 - 15:30, room Osaka/Samarkand
Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.
May 5, 15:00 - 15:15, room Singapore
SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.
May 6, 15:30 - 15:45, room Singapore
Skyepharma is a leading CDMO specializing in innovative drug delivery and bioproduction solutions. Based in France, it offers end-to-end services, from formulation development to commercial manufacturing. Its proprietary Skyehub-Bioproduction® model provides biotech companies with fully equipped GMP facilities and expert resources. With expertise in modified-release formulations, complex generics, and highly potent compounds, Skyepharma delivers customized solutions.
May 6, 16:00 - 16:15, room Osaka/Samarkand
TANDEM Tx is pioneering a mechano-targeted therapeutic platform designed to selectively target the extracellular matrix in fibrotic diseases. TANDEM’s peptide drug conjugates target mechanical changes in fibrotic niche, to home-in with precision while minimising off-target effects. This breakthrough approach can potentially transform fibrosis treatment across multiple organs. Our lead program is focused on progressive pulmonary fibrosis, a fatal disease with no cure.
May 5, 15:15 - 15:30, room Singapore
TFS HealthScience is a global contract research organization that partners with biotechnology and pharmaceutical companies throughout their entire clinical development journey. With industry-leading expertise in key therapeutic areas and demand-driven strategic resourcing, TFS can meet the needs of our partners and sponsors. Our experts are passionate about their disciplines, continually learning, enhancing and dedicating themselves to the success of your trial.
May 5, 17:45 - 18:00, room Osaka/Samarkand
Vaderis is a clinical stage biotech based in Basel, specialising in rare diseases associated with vascular malformations. Vaderis's lead compound, known as VAD044, is a novel allosteric AKT-inhibitor which has Fast-Track designation granted by FDA. VAD044 is used for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), an Orphan disease for which there are no approved therapies. VAD044 enters Phase 3 trials in 2025 and is years ahead of all HHT competitors.
May 6, 15:00 - 15:15, room Montreal
Versameb AG is a clinical-stage biotechnology company pioneering RNA-based therapeutics to address unmet medical needs. Its proprietary VERSagile platform optimizes RNA functionality for enhanced therapeutic potential. Lead candidate VMB-100, a novel mRNA therapy for stress urinary incontinence (SUI), is advancing to Phase 2a trials in 2025. Based in Basel, Versameb is committed to transforming medicine through innovative RNA science.
May 5, 15:00 - 15:15, room Montreal
Unlock the full potential of your injectable product!
Backed by 45 years of global experience, our technical, scientific, and operational expertise has made us a trusted CDMO partner for parenteral drug owners worldwide.
Discover how we keep injectable products on the path to success.
Get in touch regarding:
- Drug product development
- Clinical Manufacturing
- Analytical services
- Regulatory support
May 6, 13:00 - 13:15, room Osaka/Samarkand
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We are working on advancing antibody-based therapies that enhance the immune system’s ability to combat these potentially life-threatening diseases. Since 2025, Humabs BioMed AG (acquired by Vir Biotechnology in 2017) and Vir Biotechnology operate with a unified brand.
May 5, 15:30 - 15:45, room Montreal
